title: A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury.
abstract: Although Lp(a) have been thought to be a cardiovascular risk factor, it is unclear whether lowering Lp(a) levels reduces the risk of cardiovascular diseases. No pharmacological agents which selectively reduce serum Lp(a) levels, and Lp(a) is present in primate but absent in common laboratory animals such as mice and pigs. In the present study we used transgenic mice of human Lp(a) and tested effect a novel Lp(a) lowering drug D-47 on neointima formation after vascular injury. D-47 successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties of Lp(a) by reducing plasma levels of Lp(a). J. Med. Invest. 64: 64-67, February, 2017.
authors.affiliation: Department of Nutrition and Metabolism, Institute of Biomedical sciences, Tokushima University Graduate School.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakaya
authors.forename: Daiju
authors.initials: D
authors.lastname: Fukuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Oyamada
authors.forename: Kazuo
authors.initials: K
authors.lastname: Ogawa
authors.forename: Nagakatsu
authors.initials: N
authors.lastname: Harada
authors.forename: Hironori
authors.initials: H
authors.lastname: Nakagami
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Morishita
authors.forename: Masataka
authors.initials: M
authors.lastname: Sata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakaue
mesh_terms: D000818:Animals; D005263:Femoral Artery / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D006801:Humans; D062425:Hydroxybenzoate Ethers / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D017270:Lipoprotein(a) / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D058426:Neointima / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000494:pharmacology; D011145:Polyvinyls / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000097:blood / Q000235:genetics; D057772:Vascular System Injuries / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: C402801:4-(1-(4-tert-butylphenyl)-2-oxopyrrolidine-4-yl)methyloxybenzoic acid; D062425:Hydroxybenzoate Ethers; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D011145:Polyvinyls; D011760:Pyrrolidinones; D011994:Recombinant Proteins; C572167:polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; D011092:Polyethylene Glycols